Eiger BioPharmaceuticals Inc【EIGR】株式ニュース | ADVFN

US Dollar vs Yen

登録してリアルタイムのチャート、分析ツール、価格を入手してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Eiger BioPharmaceuticals Inc (EIGR)
Eiger BioPharmaceuticals Inc (EIGR) ニュース

Eiger BioPharmaceuticals Inc (EIGR)

1.725

0.00

( 0.00% )

更新日時： 09:00:00

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Eiger BioPharmaceuticals to Focus on Metabolic Diseases with Avexitide; David Apelian Takes Helm as CEO

Eiger BioPharmaceuticals to Focus on Metabolic Diseases with Avexitide; David Apelian Takes Helm as CEO PR...

Eiger BioPharmaceuticals to Host Business Update Call Tomorrow

Eiger BioPharmaceuticals to Host Business Update Call Tomorrow PR Newswire PALO ALTO, Calif., June 28, 2023...

Current Report Filing (8-k)

CA false 0001305253 0001305253 2023-06-15 2023-06-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ...

Quarterly Report (10-q)

falseQ1000130525312-3120230.100013052532023-01-012023-03-3100013052532023-05-08xbrli:shares00013052532023-03-31iso4217:USD00013052532022-12-3100013...

Current Report Filing (8-k)

false000130525300013052532023-05-112023-05-11UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549_________________________________...

Eiger BioPharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

Eiger BioPharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update PR...

Eiger BioPharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Eiger BioPharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) PR Newswire PALO ALTO...

Annual Report to Security Holders (ars)

Additional Proxy Soliciting Materials (definitive) (defa14a)

SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No...

Proxy Statement (definitive) (def 14a)

SCHEDULE 14A INFORMATIONProxy Statement Pursuant to Section 14(a) of theSecurities Exchange Act of 1934(Amendment No. ) Filed by the...

Current Report Filing (8-k)

CA false 0001305253 0001305253 2023-04-12 2023-04-12 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ...

Eiger BioPharmaceuticals Strengthens Management Team with New Appointments

Eiger BioPharmaceuticals Strengthens Management Team with New Appointments PR Newswire PALO ALTO, Calif...

1
2
3
次へ

Renee

EIGRQ: BK PLAN effective. All shares cancelled.

https://otce.finra.org/otce/dailyList?viewType=Deletions

Renee

EIGR changed to EIGRQ, bankruptcy. Delisted from the Nasdaq to the OTC: ***PPS at $1.72 in after hours.

https://otce.finra.org/otce/dailyList?viewType=Additions

2020trader

2020trader 9月前

down 10% today, expecting lower

2020trader

2020trader 10月前

2020trader

2020trader 10月前

expecting lower

Awl416

Awl416 10月前

Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection

Awl416

Awl416 10月前

Disquisition

Disquisition 1年前

INDEFATIGABLE DUMPING

glenn1919

glenn1919 1年前

EIGR............................................https://stockcharts.com/h-sc/ui?s=EIGR&p=W&b=5&g=0&id=p86431144783

glenn1919

glenn1919 1年前

EIGR.......................................https://stockcharts.com/h-sc/ui?s=EIGR&p=W&b=5&g=0&id=p86431144783

Monksdream

Monksdream 1年前

EIGR new 52 week low

Triple nickle

Triple nickle 2年前

Disquisition

Disquisition 2年前

HORRENDOUS DUMPING

make it happen

make it happen 3年前

$50,000,000 share offering. This is adding approximately 1/6 the structure. Decent dilution still not enough to keep the doors open for a year.

TrendTrade2016

TrendTrade2016 3年前

TrendTrade2016

TrendTrade2016 3年前

TrendTrade2016

TrendTrade2016 3年前

TrendTrade2016

TrendTrade2016 3年前

monster rare drug play

TrendTrade2016

TrendTrade2016 3年前

very nice push coming....rare disease drugs are expensive!!

make it happen

make it happen 3年前

Literally losing over $440,000,000 million a year with only 3.4 mil revenue... Covid is a semi thing of the past now. This has potential to do a reverse split again imho in a year or 2. Not bashing but financials can't add up like this. Hi I'm spending half a Billion dollars a year and have basically zero revenue. Where's this going to come from to keep it going?

make it happen

make it happen 3年前

Volume is not sustainable imo and did a 15 to 1 Reverse split. They don't even have enough cash to cover 1 quarter. Was $0.86

TrendTrade2016

TrendTrade2016 3年前

watch and learn loser

make it happen

make it happen 3年前

Mid tripple digit negative profitability over 600% NEGATIVE. I don't think I have ever seen such big negative numbers on any ticker my entire life. While burning over $110,000,000 million a quarter... with revenues of 3 mil..

Profitability
Profit Margin -279.34%
Operating Margin (ttm) -633.66%

Management Effectiveness
Return on Assets (ttm) -35.62%
Return on Equity (ttm) -40.51%

Income Statement
Revenue (ttm) 12.14M
Revenue Per Share (ttm) 0.36
EBITDA -76.66M
Net Income Avi to Common (ttm) -33.92M
Diluted EPS (ttm) -1.00

Cash Flow Statement
Operating Cash Flow (ttm) -71.34M
Levered Free Cash Flow (ttm) -41.5M

TrendTrade2016

TrendTrade2016 3年前

TrendTrade2016

TrendTrade2016 3年前

massive bio play taking off in pre!

ae kusterer

ae kusterer 4年前

jhpratt@alphavestcapital.com is my email.Please email me insights into eigr.

alphavestcapital.com

MOST IMPORTANT SUMMARY SENTENCES IN THE LANCET ARTICLE:(paraphrased: EIGR’s interferon works better than monoclonal antibodies at reducing covid viral load.Plus, EIGR’s interferon can be administered on an outpatient basis. )"Added value of this study This study shows that a single subcutaneous injection of 180 µg peginterferon lambda has an antiviral effect in outpatients with COVID-19. The decline in viral load was greater with peginterferon lambda treatment than with placebo. The more rapid viral load decline and higher clearance rate were most pronounced in those with high viral loads, a finding also reported with monoclonal antibody therapies in patients with COVID-19. However, the magnitude of the viral load decline compared with that of placebo was much greater with peginterferon lambda than has been reported with monoclonal antibody therapies to date. Peginterferon lambda was safe and well tolerated in outpatients with mild-to-moderate COVID-19, with a similar side-effect profile to that of placebo and no concerning laboratory adverse events. Implications of all the available evidence No approved therapy exists for outpatients with COVID-19. This study showed that peginterferon lambda accelerated viral clearance, particularly in those with high baseline viral loads, highlighting the importance of quantitative viral load testing in the assessment of antiviral agents for patients with COVID-19. Treatment early in the course of disease might prevent clinical deterioration and shorten the duration of viral shedding, which might have an important public health effect by reducing transmission and reducing the duration of self-isolation."

Penny chatter

Penny chatter 4年前

Dead though lol

TheFinalCD

TheFinalCD 4年前

more NEWS https://ih.advfn.com/stock-market/NASDAQ/eiger-biopharmaceuticals-EIGR/stock-news/83743438/eiger-biopharmaceuticals-sells-priority-review-vou

Oger

Let’s go over $20...

Penny chatter

Penny chatter 4年前

They say the right things in the conference call it should go bananas. The drug does have covid implications https://twitter.com/Goldbarstocks/status/1330608767055106048?s=19

Oger

You think this rocks tomorrow penny chatter?

Penny chatter

Penny chatter 4年前

Think someone will be stated it. I looked and couldn't find it

Oger

Who’s the buyer?
I couldn’t find it...

Penny chatter

Penny chatter 4年前

Folks miss the covid implications here and they already have a buyer here https://twitter.com/Goldbarstocks/status/1330608767055106048?s=19

Oger

It will sink it the magnitude of this drug, extending the life of these
children 2-1/2 years ....

Penny chatter

Penny chatter 4年前

I agree as it has 80% institutional ownership

Oger

Over $20 on Monday......

Penny chatter

Penny chatter 4年前

They didn't have to halt for this lol

TheFinalCD

TheFinalCD 4年前

https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-hutchinson-gilford-progeria-syndrome-and-some-progeroid-laminopathies

https://medlineplus.gov/genetics/condition/hutchinson-gilford-progeria-syndrome/

Progeria
Also known as: hutchinson-gilford progeria syndrome
OVERVIEW
SYMPTOMS
DIAGNOSIS
TREATMENT
A progressive genetic disorder where symptoms of aging are manifested at an early age.
How common is condition?
Extremely rare (Fewer than 1,000 cases per year in US)
Is condition treatable?
Treatments can help manage condition, no known cure
Does diagnosis require lab test or imaging?
Requires lab test or imaging
Condition Highlight
Present at birth, onset can be infantile or juvenile
Condition Highlight
May be dangerous or life threatening
Condition Highlight
Family history may increase likelihood

Penny chatter

Penny chatter 4年前

What kind of fda approval don't see interest?

Penny chatter

Penny chatter 4年前

TheFinalCD

TheFinalCD 4年前

HALTED PENDING NEWS 11/20/2020 16:53:30 EIGR Eiger BioPharma NASDAQ
T1

Fezziwig2008

Fezziwig2008 4年前

EIGR - Lambda is most paradoxical interferon :
“ IFN-lambda responses to dsRNA in the human infant airway epithelium are regulated by p38-MAPK and NF-kB signaling. High in vivo IFN-lambda production is influenced by virus type and associated with recurrent respiratory sick visits in young children.”

https://scholar.google.com.hk/scholar?start=50&q=interferon+lambda&hl=en&as_sdt=0,33&as_ylo=2020#d=gs_qabs&u=%23p%3DpIKe3q7igMIJ

MWM

A mutual friend we have really likes it.

Small share structure is compelling...

Fezziwig2008

Fezziwig2008 4年前

EIGR is expected to release interim data from its Stanford Lambda Trial - I’m not too excited, given the emergent need for any slightly positive data regarding the treatment of SARS2 -see Remdesivir 4 day advantage- and the failure of the data monitoring committee - who already had their interim look/- to halt the study on efficacy - a little bird told me (when I was a vocal advocate of EIGR on Twitter)- that the data was less than compelling to that point weeks ago - certainly that might have changed. The recent insider buy certainly makes on hopeful that it has. A recent seeking alpha pump suggests the upcoming Progeria approval carries tge rest of the pipeline - have you seen how rare Progeria is?

MWM

https://seekingalpha.com/instablog/52316800-friar-tuck-esq/5480909-eiger-biopharmaceuticals-low-risk-biotech-10-bagger-near-term-catalyst

MWM

$EIGR what is Cooking?

MWM

EIGR is cooking...

Fezziwig2008

Fezziwig2008 4年前

EIGR ”Although no synthetic IFN-lambda is yet FDA-approved, preliminary results in a clinical trial in hepatitis D patients show that it has the same antiviral potency as type I IFN but is much safer and better tolerated. A study in mice found that synthetic IFN-lambda was as effective as IFN-alpha in treating influenza but didn’t have the same proinflammatory effects.”
https://www.frontiersin.org/articles/10.3389/fneur.2020.00146/full

Fezziwig2008

Fezziwig2008 4年前

On EIGR (Lambda is IFN III) “Treatment with type I and III IFNs can dramatically inhibit SARS-CoV-2 replication in primary human airway epithelial cells with the corresponding induction of ISGs.22 The role of type III IFNs in the suppression of virus replication has been highlighted.23,24 Type III IFN shows a better treatment option than type I IFN for influenza A virus-induced disease for its induction of antiviral immunity without the pro-inflammatory responses.”

https://www.biorxiv.org/content/10.1101/2020.07.26.222026v1.full.pdf

Eiger BioPharmaceuticals

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約